For people with HIV, there’s a new drug on the block that promises to deliver a powerful punch: Aptivus, a drug in the protease inhibitor (PI) class approved by the FDA in June. It has a unique resistance profile—meaning that if your virus has developed resistance to protease inhibitors, Aptivus might still work for you. Another PI expected to give treatment-resistant HIVers new hope, TMC-114, is also inching its way toward FDA approval and pharmacy shelves.